


MASH DRUG DEVELOPMENT

A COMPETITIVE EDGE FOR CLINICAL DEVELOPMENT

INTEGRATED MASH EXPERIENCE



IMAGING CORE LABORATORY

MR- and Ultrasound-Based Biomarkers for MASH Studies

- Quantitative Volumetric Imaging (MRI)
- Proton Density Fat Fraction (MRI-PDFF)
- Elastography (MRE)
- Spectroscopy (MRS)
- Vibration Controlled Transient Elastography +/- Controlled Attenuation Parameter (VCTE+/-CAP)

STRATEGIC EXECUTION

Expert Management

- Experienced Operational Teams
- In-House Physicians
- Global Regulatory

GLOBAL EXPERIENCE

Nash Trial Management Since 2010

15
COUNTRIES

3300+
PATIENTS

850+
SITES

CENTRAL LAB CAPABILITIES

MASH Biomarker Strategic Services

- Cytokeratin - 18 (M30 and M65)
- Apolipoprotein A1
- Apolipoprotein B
- Leptin
- Adiponectin
- Resistin
- Free Fatty Acids
- Ghrelin
- Interleukin-6
- TNF α
- ELF: TIMP-1, HA, P3NP
- Histology & Anatomic Pathology

INTEGRATED EFFICIENCY


A Model Of Collaboration – An End To End Partner



- Central Labs
- Bioanalytical Lab
- Core Labs
- Phase I Unit

THERAPEUTIC FOCUS

Scientific Expertise Embedded In Trials—Hands-On & Specialized



MAKING THE COMPLEX
SEAMLESS®

ORGANIC GROWTH

*Stable And Disciplined—
Preserving A Culture Of Quality*



What's The Difference?

30+ year history

Embedded physician leadership

Strategic regulatory affairs

Scientific reputation and relationships

One-of-a-kind research campus

ClinTrak®

Budget management model

Rigorous training program

Office-based model

Why It Matters

Stability in leadership and deep institutional experience

Therapeutic expertise through trial lifecycle

Early planning for long term success

Access to KOLs and sites

Built-in efficiency

Technology for proactive study management

Operations focused on execution

Consistent quality around the world

Facilitates collaboration and communication

GLOBAL REACH

*Operational Around
The World—Wherever
Research Is Happening*



CENTRAL LAB LOCATIONS

USA | Belgium | China | Singapore